Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes

Dong,Bohan; Dai,Guangli; Xu,Lei; Zhang,Yao; Ling,Liefeng; Sun,Lingling; Lv,Jun

doi:10.3892/mmr.2014.2606

Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes

Authors:
- Bohan Dong
- Guangli Dai
- Lei Xu
- Yao Zhang
- Liefeng Ling
- Lingling Sun
- Jun Lv
View Affiliations

Affiliations: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Department of Gynaecology and Obstetrics, Traditional Chinese Medical Hospital of Wuhu, Wuhu, Anhui 241000, P.R. China
Published online on: October 2, 2014 https://doi.org/10.3892/mmr.2014.2606
Pages: 2827-2834
Copyright: © Dong et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although tumor cell lysate (TCL) is a type of immunocyte stimulator, its immunosuppressive function must not be ignored. The present study reported that TCL prepared from a Lewis lung cancer cell was able to induce the development of immunosuppressive macrophages (MΦ) and tolerogenic dendritic cells. In addition, TCL upregulated the expression of CD69 in mouse splenocytes, and cell apoptosis and the percentage of regulatory T cells in mouse splenocytes simultaneously increased. Furthermore, the present study found that the immunosuppressive factor, hyaluronan, and the apoptosis inducers, Fas ligand and transforming growth factor-β, are present in TCL. These components may be associated with the emergence of immunosuppressive cells or splenocyte apoptosis. Thus, the present study has enriched our understanding of the composition of TCL and its negative regulatory effect on immunocytes.

View Figures

View References

1	Yang DH, Park JS, Jin CJ, et al: The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res. 33:665–670. 2009. View Article : Google Scholar
2	Dong B, Sun L, Wu X, et al: Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice. Cancer Immunol Immunother. 59:899–908. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kuang DM, Zhao Q, Xu J, Yun JP, Wu C and Zheng L: Tumor-educated tolerogenic dendritic cells induce CD3 down-regulation and apoptosis of T cells through oxygen-dependent pathways. J Immunol. 181:3089–3098. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM and Zheng L: Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood. 110:587–595. 2007. View Article : Google Scholar
5	Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
6	Chuster N and Krieglstein K: Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res. 307:1–14. 2002. View Article : Google Scholar : PubMed/NCBI
7	Niehans GA, Brunner T, et al: Human lung carcinomas express Fas ligand. Cancer Res. 57:1007–1012. 1997.PubMed/NCBI
8	Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F and Mor G: The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat. 54:245–253. 1999. View Article : Google Scholar : PubMed/NCBI
9	Saji H, Nakamura H, Awut H, et al: Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg. 9:295–300. 2003.
10	Imai K, Minamiya Y, Goto A, et al: Bronchioloalveolar invasion in non-small cell lung cancer is associated with expression of transforming growth factor-β1. World J Surg Oncol. 11:1132013.PubMed/NCBI
11	Kim HR, Wheeler MA, Wilson CM, et al: Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44. Cancer Res. 64:4569–4576. 2004. View Article : Google Scholar : PubMed/NCBI
12	Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV and Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res. 60:150–155. 2000.PubMed/NCBI
13	Auvinen P, Tammi R, Parkkinen J, et al: Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol. 156:529–536. 2000. View Article : Google Scholar : PubMed/NCBI
14	Subramanian G, Schwarz RE and Higgins L: Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient pancreatic carcinoma cells inhibits their invasive phenotypel. Cancer Res. 64:5200–5211. 2004. View Article : Google Scholar
15	Grimm M, Gasser M, Bueter M, et al: Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer. 10:822010. View Article : Google Scholar : PubMed/NCBI
16	Jansen T, Tyler B, Mankowski JL, et al: FasL gene knock-down therapy enhances the antiglioma immune response. Neuro Oncol. 12:482–489. 2010.PubMed/NCBI
17	Hahne M, Rimoldi D, Schroter M, et al: Melanoma cell expressing of Fas (Apo1-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363–1366. 1996. View Article : Google Scholar : PubMed/NCBI
18	Haidong D, Scott ES, Diva RS, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8:793–800. 2002.PubMed/NCBI
19	Quesnel B: Tumor dormancy and immunoescape. APMIS. 116:685–694. 2008. View Article : Google Scholar : PubMed/NCBI
20	Attia P, Powell DJ Jr, Maker AV, Kreitman RJ, Pastan I and Rosenberg SA: Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother. 29:208–214. 2006. View Article : Google Scholar : PubMed/NCBI
21	Radstake TR, van Bon L, Broen J, et al: Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFb expression. PLoS One. 4:e59812009. View Article : Google Scholar
22	Chiang CL, Benencia F and Coukos G: Whole tumor antigen vaccines. Semin Immunol. 22:132–143. 2010. View Article : Google Scholar : PubMed/NCBI
23	Kawahara M and Takaku H: Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice. Int J Oncol. 43:2023–2030. 2013.PubMed/NCBI
24	Mytar B, Woloszyn M, Szatanek R, et al: Tumor cell-induced deactivation of human monocytes. J Leukoc Biol. 74:1094–1101. 2003. View Article : Google Scholar : PubMed/NCBI
25	Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
26	Kryczek I, Wei S, Zou L, et al: Cutting edge: induction of B7–H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol. 177:40–44. 2006.
27	Bennett MW, O’connell J, O’sullivan GC, et al: Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 44:156–162. 1999. View Article : Google Scholar : PubMed/NCBI
28	Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 29:117–129. 2001. View Article : Google Scholar : PubMed/NCBI
29	Pajusto M, Ihalainen N, Pelkonen J, et al: Human in vivo activated CD45R0(⁺) CD4(⁺) T cells are susceptible to spontaneous apoptosis that can be inhibited by the chemokine CXCL12 and IL-2, -6. -7 and -15. Eur J Immunol. 34:2771–2780. 2004.PubMed/NCBI
30	Esplugues E, Vega-Ramos J, Cartoixa D, et al: Induction of tumor NK-cell immunity by anti-CD69 antibody therapy. Blood. 105:4399–4406. 2005. View Article : Google Scholar : PubMed/NCBI
31	Ralainirina N, Poli A, Michel T, Poos L, Andrès E, Hentges F and Zimmer J: Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol. 81:144–153. 2007. View Article : Google Scholar : PubMed/NCBI
32	Radosavljević GD, Jovanović IP, Kanjevac TV and Arsenijević NN: The role of regulatory T cells in the modulation of anti-tumor immune response. Srp Arh Celok Lek. 141:262–267. 2013.(In Serbian).
33	David S, Manuel G and Francisco SM: CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 26:136–140. 2005. View Article : Google Scholar : PubMed/NCBI
34	Freedman RS, Kudelka AP, Kavanagh JJ, et al: Clinical and biological effects of intraperitoneal injections of recombinant interferongamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res. 6:2268–2278. 2000.
35	Esplugues E, Sancho D, Vega-Ramos J, et al: Enhanced antitumor immunity in mice deficient in CD69. J Exp Med. 197:1093–1106. 2003. View Article : Google Scholar : PubMed/NCBI
36	Schwenk R, Banania G, Epstein J, et al: Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8⁺ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1. Malar J. 12:3762013. View Article : Google Scholar